Comparative Pharmacology
Head-to-head clinical analysis: ALDURAZYME versus REVCOVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDURAZYME versus REVCOVI.
ALDURAZYME vs REVCOVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALDURAZYME (laronidase) is a recombinant form of human α-L-iduronidase, an enzyme that hydrolyzes terminal α-L-iduronic acid residues in glycosaminoglycans (GAGs) such as dermatan sulfate and heparan sulfate. It replaces the deficient enzyme in patients with mucopolysaccharidosis I (MPS I), reducing lysosomal accumulation of GAGs.
Recombinant adenosine deaminase (ADA) enzyme replacement therapy; degrades adenosine and deoxyadenosine, reducing toxic metabolites and restoring immune function.
0.58 mg/kg administered intravenously once weekly.
25 mg/kg body weight administered intramuscularly once weekly.
None Documented
None Documented
Terminal half-life: 6–10 minutes (rapid clearance from plasma due to cellular uptake via mannose-6-phosphate receptors); clinical context: clearance is saturable, leading to longer effective half-life at therapeutic doses
Terminal elimination half-life is approximately 3-6 months (mean ~100 days) in patients with PEG-ADA deficiency; clinical context: sustained enzyme replacement allows weekly or biweekly dosing.
Renal: negligible; primarily catabolism via peptide hydrolysis; no significant biliary/fecal elimination
Renal excretion of unchanged drug and metabolites: approximately 100% eliminated renally; no significant biliary/fecal elimination.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy